Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21751436 | 0.71 | PRKD3 (0.44) | KMT2A | |
| SCHEMBL789290 | 0.71 | PRKD3 (0.44) | KMT2A | |
| SCHEMBL15870316 | 0.71 | PRKD3 (0.44) | KMT2A | |
| SCHEMBL2479329 | 0.66 | FFAR3 (0.38) | TSHRALDH1A1 | |
| SCHEMBL13148260 | 0.65 | TSHR (0.41) | TSHRKMT2AALDH1A1ESR1HSD17B10 | |
| SCHEMBL7762152 | 0.65 | PTPN1 (0.36) | — | |
| SCHEMBL28677870 | 0.64 | KMT2A (0.44) | TSHRKMT2AALDH1A1ESR1HSD17B10 | |
| SCHEMBL21771475 | 0.64 | CHRM2 (0.33) | KMT2A | |
| SCHEMBL20617833 | 0.63 | TSHR (0.39) | TSHRKMT2AALDH1A1ESR1HSD17B10 | |
| SCHEMBL28011826 | 0.63 | TSHR (0.42) | TSHRKMT2AALDH1A1ESR1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7390875-B2 | Method for binding, in solution, a peptide and a lipophilic vector and uses thereof | INSTITUT PASTEUR DE LILLE (FR) | 2008-06-24 | — | — | US | disclosed |
| US-20040092015-A1 | Method for binding, in solution, a peptide and a lipophilic vector and uses thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS (FR) | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092015-A1 | Method for binding, in solution, a peptide and a lipophilic vector and uses thereof | VIP, LIPE, LPXN | TSHR 1149/4885KMT2A 3299/4885ALDH1A1 1587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.